European commitments to TB R&D investments: Promises made to be broken?
A brief, released by Treatment Action Group, outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.
In the past, European countries contributed a great deal to TB research and development, leading to groundbreaking discoveries like the mycobacterial cause of the disease and the 100-year-old the bacillus Calmette-Guérin (BCG) vaccine. However, since the 2018 United Nations High-Level Meeting on TB, high hopes for European investments have not been realized. European Union (EU) member states have failed to contribute their fair share of funding toward the $2 billion needed globally each year to make TB elimination possible within a generation.
Treatment Action Group (TAG) released a brief outlining the pathway the EU can take to scale up support for TB research and development (R&D), and advance the many European-sponsored TB vaccine candidates currently in the development pipeline. Outlining EU-wide and country-specific funding targets, and examples of successful initiatives thus far, this proposal offers ambitious and realistic guidelines for creating a TB-free future.
To download the brief, click here.
Source: Treatment Action Group
